Dysregulation of insulin secretion in children with congenital hyperinsulinism due to sulfonylurea receptor mutations

Diabetes

Volumn 50, Issue 2, 2001, Pages 322-328

  Grimberg, A ^a   Ferry Jr , R J ^a   Kelly, A ^a   Koo McCoy, S ^a   Polonsky, K ^b   Glaser, B ^c   Permutt, M A ^d   Aguilar Bryan, L ^e   Stafford, D ^f   Thornton, P S ^g   Baker, L ^a   Stanley, Charles A ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d WASHINGTON UNIVERSITY   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g Children's University Hospital   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; POTASSIUM CHANNEL; SULFONYLUREA; SULFONYLUREA RECEPTOR; TOLBUTAMIDE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HUMAN; HYPERINSULINISM; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; PANCREAS RESECTION; PRIORITY JOURNAL; RECESSIVE INHERITANCE;

EID: 0035142144     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.50.2.322     Document Type: Article

References (51)

1. Genetics of neonatal hyperinsulinism
2. Hyperinsulinism in infants and children
3. Familial hyperinsulinism caused by an activating glucokinase mutation
4. Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene
5. Familial hyperinsulinism with apparent autosomal dominant inheritance: Clinical and genetic differences from the autosomal recessive variant
6. An autosomal dominant form of familial persistent hyperinsulinemic hypoglycemia of infancy, not linked to the sulfonylurea receptor locus
7. Homozygosity mapping to chromosome 11p of the gene for familial persistent hyperinsulinemic hypoglycemia of infancy
8. The molecular basis for familial persistent hyperinsulinemic hypoglycemia of infancy
9. Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy
10. Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy
11. A nonsense mutation in the inward rectifier potassium channel gene, Kir6.2, is associated with familial hyperinsulinism
12. Reconstitution of IKATP: An inward rectifier subunit plus the sulfonylurea receptor
13. + channels: Generating excitement in pancreatic beta-cells
14. Endogenous hyperinsulinism: Diagnosis, management, and long-term follow-up
15. Hyperinsulinemic hypoglycemia of infancy (nesidioblastosis) in clinical remission: High incidence of diabetes mellitus and persistent beta-cell dysfunction at long-term follow-up
16. Congenital hyperinsulinism and the surgeon: Lessons learned over 35 years
17. Paternal mutation of the sulfonylurea receptor (SUR1) gene and maternal loss of 11p15 imprinted genes lead to persistent hyperinsulinism in focal adenomatous hyperplasia
18. Hyperinsulinism: Molecular aetiology of focal disease
19. Hyperinsulinism caused by paternal-specific inheritance of a recessive mutation in the sulfonylurea-receptor gene
20. Toward understanding the assembly and structure of KATP channels
21. A view of sur/KIR6.X, KATP channels
22. Sulfonylurea receptors: ABC transporters that regulate ATP-sensitive K(+) channels
23. Adenosine diphosphatase as an intracellular regulator of insulin secretion
24. ATP-sensitive potassium channels, sulfonylurea receptors, and persistent hyperinsulinemic hypoglycemia of infancy
25. Mutations in the sulfonlurea receptor gene are associated with familial hyperinsulinism in Ashkenazi Jews
26. Familial hyperinsulinism maps to chromosome 11p14-15.1, 30 cM centromeric to the insulin gene
27. Tolbutamide tolerance test and plasma-insulin response in children with idiopathic hypoglycemia
28. Diagnostic interpretation of the intravenous tolbutamide test for insulinoma
29. Familial persistent hyperinsulinemic hypoglycemia of infancy and mutations in the sulfonylurea receptor
30. The C terminus of SUR1 is required for trafficking of KATP channels
31. 2+ influx in rat pancreatic B-cell
32. - channels in mouse B cells
33. -) permeability
34. ATP channel-independent signaling pathways in human islets
35. Hyperinsulinism of infancy: Towards an understanding of unregulated insulin release
36. 2+ in mouse islets of Langerhans
37. 2+ release at the endoplasmic reticulum in rat pancreatic β-cells
38. Calcium influx and afflux pathways in insulin-secreting cells
39. Glucose stimulates voltage- and calcium-dependent inositol triphosphate production and intracellular calcium mobilization in insulin-secreting BTC3 cells
40. 2+ stores activates a maitotoxin-sensitive nonselective cationic current in β-cells
41. i oscillations in transgenic-derived β-cells
42. cAMP enhances insulin secretion by an action on the ATP-sensitive K+ channel-independent pathway of glucose signaling in rat pancreatic islets
43. Surl knockout mice: A model for K(ATP) channel-independent regulation of insulin secretion
44. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations
45. Altered insulin secretory responses to glucose in diabetic and nondiabetic subjects with mutations in the diabetes susceptibility gene MODY3 on chromosome 12
46. Maturity-onset diabetes of the young
47. Abnormal insulin secretion, not insulin resistance, is the genetic or primary defect of MODY in the RW pedigree
48. Glucose potentiation of arginine-induced insulin secretion is impaired in subjects with a glucokinase Glu256Lys mutation
49. Defects in beta-cell function and insulin sensitivity in normoglycemic streptozocin-treated baboons: A model of preclinical insulin-dependent diabetes
50. A role for endogenous prostaglandins in defective glucose potentiation of nonglucose insulin secretagogues in diabetics
51. Potentiation and inhibition of insulin release in man following priming with glucose and with arginine: Effect of somatostatin